Cetirizine overdose in a young child
Available from: nature.com
- "Further progress with regard to drug safety was achieved by the development of the antihistamines cetirizine, fexofenadine, and descarboxyloratadine, which are cytochrome P450-independent metabolites of earlier antihistamines . The highest reported accidental overdose of antihistamine (50-fold of the prescribed dose of cetirizine in an 18-mo-old boy) induced no adverse effects other than sleepiness (Ridout and Tariq, 1997). The main drug interactions have been described until recently for sedating antihistamines in association with drugs affecting the central nervous system like analgetics, hypnotics, sedatives, and mood elevating drugs, as well as alcohol. "
[Show abstract] [Hide abstract]
ABSTRACT: This consensus report is the result of a panel discussion during the International Clinically Oriented ESDR Symposium Urticaria 2000. Urticaria has a profound impact on the quality of life and effective treatment is required. The most important are nonsedating H1 antihistamines. They have been proven to be effective in double-blind controlled studies, but concentrations higher than those recommended may be necessary. Due to different urticaria subtypes and the individual variation in the course of the disease and response to treatment, however, alternative therapies may be required. Immunosuppressive drugs like cyclosporine A and corticosteroids should not be used long term due to undesirable side-effects.
Journal of Investigative Dermatology Symposium Proceedings 12/2001; 6(2):128-31. DOI:10.1046/j.0022-202x.2001.00023.x · 3.73 Impact Factor
Drugs 01/2004; 64(5). DOI:10.2165/00003495-200464050-00008 · 4.34 Impact Factor
Paediatric Drugs 01/1999; 1(1). DOI:10.2165/00128072-199901010-00005 · 1.98 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.